A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/663 (2006.01) A61K 9/00 (2006.01) A61K 47/12 (2006.01) A61P 19/08 (2006.01)
Patent
CA 2190148
Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.
L'invention concerne un protocole de thérapie destiné au traitement et à la prévention de la perte osseuse, chez des patients présentant des difficultés d'absorption, par administration d'une formulation liquide d'alendronate pouvant être facilement absorbée. L'invention concerne également des formes galéniques pharmaceutiques d'un sirop, d'une solution aqueuse, d'une solution formée à partir d'une poudre reconstituée, d'alendronate, permettant l'application du procédé thérapeutique.
Brenner Gerald S.
Katdare Ashok V.
Pretzer Denise
Whiteford Donna T.
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Oral liquid alendronate formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral liquid alendronate formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral liquid alendronate formulations will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2065630